Literature DB >> 8887627

Basal phosphorylation of the PEST domain in the I(kappa)B(beta) regulates its functional interaction with the c-rel proto-oncogene product.

Z L Chu1, T A McKinsey, L Liu, X Qi, D W Ballard.   

Abstract

The product of the c-rel proto-oncogene (c-Rel) belongs to the NF-kappaB/Rel family of polypeptides and has been implicated in the transcriptional control of cell proliferation and immune function. In human T lymphocytes, c-Rel is sequestered in the cytoplasmic compartment by constitutively phosphorylated inhibitors, including I(kappa)B(alpha) and I(kappa)B(beta). Studies with bacterially expressed forms of these inhibitory proteins revealed that unphosphorylated I(kappa)B(alpha) but not I(kappa)B(beta) assembles with c-Rel and inhibits its DNA binding activity. Furthermore, latent I(kappa)B(beta)-c-Rel complexes derived from mammalian cells were sensitive to phosphatase treatment, whereas I(kappa)B(alpha)-c-Rel complexes were resistant. We have identified a constitutive protein kinase in unstimulated T cells that associates with and phosphorylates I(kappa)B(beta) in vitro. The substrate specificity, electrophoretic mobility, and antigenic properties of this I(kappa)B(beta)-associated kinase (BAK) suggest identity with casein kinase II (CKII), an enzyme known to mediate basal phosphorylation of I(kappa)B(alpha). Phosphorylation of recombinant I(kappa)B(beta) by either BAK or CKII restored the capacity of this inhibitor to antagonize the DNA binding activity of c-Rel. Peptide mapping and mutational analyses localized the bulk of the basal phosphorylation sites in I(kappa)B(beta) to the C-terminal PEST domain, which contains two potential acceptors for CKII-mediated phosphoryl group transfer (Ser-313 and Ser-315). Point mutations introduced into the full-length inhibitor at Ser-313 and Ser-315 led to a significant reduction in the phosphorylation of I(kappa)B(beta) and severely impaired its c-Rel inhibitory function in vivo. Taken together, these findings strongly suggest that basal phosphorylation of the PEST domain of I(kappa)B(beta) at consensus CKII sites is required for the efficient formation of latent I(kappa)B(beta)-c-Rel complexes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887627      PMCID: PMC231600          DOI: 10.1128/MCB.16.11.5974

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  75 in total

1.  The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product.

Authors:  M Kieran; V Blank; F Logeat; J Vandekerckhove; F Lottspeich; O Le Bail; M B Urban; P Kourilsky; P A Baeuerle; A Israël
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

2.  NF-kappa B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells.

Authors:  J A Molitor; W H Walker; S Doerre; D W Ballard; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B.

Authors:  S M Ruben; P J Dillon; R Schreck; T Henkel; C H Chen; M Maher; P A Baeuerle; C A Rosen
Journal:  Science       Date:  1991-03-22       Impact factor: 47.728

4.  A calcium-dependent antibody for identification and purification of recombinant proteins.

Authors:  K S Prickett; D C Amberg; T P Hopp
Journal:  Biotechniques       Date:  1989-06       Impact factor: 1.993

5.  The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function.

Authors:  D W Ballard; W H Walker; S Doerre; P Sista; J A Molitor; E P Dixon; N J Peffer; M Hannink; W C Greene
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

6.  The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.

Authors:  V J Palombella; O J Rando; A L Goldberg; T Maniatis
Journal:  Cell       Date:  1994-09-09       Impact factor: 41.582

7.  Activation of the interleukin-2 receptor alpha gene: regulatory role for DNA-protein interactions flanking the kappa B enhancer.

Authors:  D W Ballard; E Böhnlein; J A Hoffman; H P Bogerd; E P Dixon; B R Franza; W C Greene
Journal:  New Biol       Date:  1989-10

8.  High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro.

Authors:  C Abbadie; N Kabrun; F Bouali; J Smardova; D Stéhelin; B Vandenbunder; P J Enrietto
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

9.  A novel NF-kappa B complex containing p65 homodimers: implications for transcriptional control at the level of subunit dimerization.

Authors:  P A Ganchi; S C Sun; W C Greene; D W Ballard
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Promoter analysis of the gene encoding the I kappa B-alpha/MAD3 inhibitor of NF-kappa B: positive regulation by members of the rel/NF-kappa B family.

Authors:  O Le Bail; R Schmidt-Ullrich; A Israël
Journal:  EMBO J       Date:  1993-12-15       Impact factor: 11.598

View more
  30 in total

1.  Alternative nuclear functions for NF-κB family members.

Authors:  Lluís Espinosa; Anna Bigas; Maria Carmen Mulero
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

Review 2.  Molecular mechanisms in lymphocyte activation and growth.

Authors:  D W Ballard
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription.

Authors:  Z Li; G J Nabel
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

4.  Inhibiting IκBβ-NFκB signaling attenuates the expression of select pro-inflammatory genes.

Authors:  Sarah McKenna; Clyde J Wright
Journal:  J Cell Sci       Date:  2015-04-23       Impact factor: 5.285

5.  Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB.

Authors:  K Kalli; C Huntoon; M Bell; D J McKean
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 6.  Specification of DNA binding activity of NF-kappaB proteins.

Authors:  Fengyi Wan; Michael J Lenardo
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10       Impact factor: 10.005

7.  Mechanisms by which IkappaB proteins control NF-kappaB activity.

Authors:  S Simeonidis; D Stauber; G Chen; W A Hendrickson; D Thanos
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

8.  Distinct domains of IkappaBalpha regulate c-Rel in the cytoplasm and in the nucleus.

Authors:  I Luque; C Gélinas
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

9.  Regulation of IkappaB beta in WEHI 231 mature B cells.

Authors:  R J Phillips; S Ghosh
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

Review 10.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.